Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Individualized Pegasys and Copegus in Chronic Hepatitis C (MASTER Study)
NCT01296971Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Dec 2009
- Primary completion
- Dec 2009
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of pegylated interferon alpha, ribavirin in hepatitis C (HCV), sponsored by Roche. Planned start Dec 2009; status: withdrawn.
02
Drugs
pegylated interferon alpharibavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01296971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01296971.